MEI Pharma Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
MEI Pharma Stock Forecast and Price Target
MEI Pharma's stock price reaches the average target of $20.00 by 2025 as expected recently by notable experts, there would be a potential upside of approximately 515.38% from the last closing price in April, 2024. This possible increase is based on a high estimate of $42.00 and a low estimate of $7.00. Even if you are not interested in MEIP stock, it is still imperative to be aware of its competitors.
515.38% Upside
MEI Pharma Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, MEI Pharma's Price has grown, moving from $0.00 to $0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will jump to $3.32 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$726.31 | Buy/Sell | $636.99 | 15.31% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$147.91 | Buy/Sell | $174.55 | 14.93% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.78 | Buy/Sell | $130.51 | 10.91% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.00 | Buy/Sell | $32.87 | 17.31% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$394.28 | Buy/Sell | $457.59 | 14.13% |
MEI Pharma Revenue Forecast for 2023 - 2025 - 2030
In the last three years, MEI Pharma's Revenue has grown, moving from $27.76M to $48.82M – an increase of 75.86%. In the following year, the 2 analysts surveyed believe that MEI Pharma's Revenue will decrease by 98.79%, reaching $590.00k. According to professionals, by 2030, MEI Pharma's Revenue will have decreased by 57.33%, falling down to $20.83M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.93 | Buy/Sell | $58.15 | 12.41% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$896.82 | Buy/Sell | $961.26 | 17.08% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$146.50 | Buy/Sell | $220.47 | 51.19% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$39.47 | Buy/Sell | $44.86 | 14.01% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$144.41 | Buy/Sell | $245.24 | 48.88% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.25 | Buy/Sell | $11.73 | 6.67% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$237.93 | Buy/Sell | $284.08 | 24.83% |
| CTLT Stock Forecast | Catalent | Hold |
15
|
$55.48 | Buy/Sell | $49.29 | 14.46% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$67.55 | Buy/Sell | $87.92 | 39.16% |
MEI Pharma EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, EBITDA for MEI Pharma has grown by 42.16%, going from $-25.59M to $-36.38M. In the coming year, analysts are expecting an increase in EBITDA, predicting it will reach $-39.92M – an increase of 9.72%. Over the next seven years, experts anticipate that EBITDA growth for MEI Pharma will be 49.37%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$40.68 | Buy/Sell | $55.60 | 47.98% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$212.04 | Buy/Sell | $315.92 | 83.93% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$143.48 | Buy/Sell | $145.00 | 13.60% |
MEI Pharma EBIT Forecast for 2023 - 2025 - 2030
MEI Pharma's EBIT has grown in the last three years, jumping from $-25.70M to $-36.76M – an increase of 43.04%. In the next year, analysts predict that EBIT will reach $-59.22M – an increase of 61.10%. By 2030, professionals believe that MEI Pharma's EBIT will decrease by 6839.12%, reaching $2.48B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$30.80 | Buy/Sell | $44.75 | 29.87% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$11.61 | Buy/Sell | $37.00 | 46.43% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$40.01 | Buy/Sell | $69.00 | 54.96% |
MEI Pharma EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, MEI Pharma's EPS has grown, moving from $-12.21 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will jump to $-7.07 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that EPS will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$13.78 | Buy/Sell | $29.44 | 146.73% |
| CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$22.95 | Buy/Sell | $35.67 | 65.58% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£15.14 | Buy/Sell | £28.89 | 108.06% |
.jpg)